Interview addressing the controversies surrounding second-line treatment regimens and the promising addition of Welireg into this setting. RCC pipeline drug combinations and available data are also discussed, as well as the need for a more organised and systematic approach to treatment combinations in the future. 

This interview was conducted on 4 April 2024. 

If you are a KOL Insight Subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.